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Expression of the sodium iodide symporter in human kidney. of iodide across the basolateral membrane of thyroid
Background. The human sodium iodide symporter (hNIS) follicular cells. Human NIS couples the energy released
is a transmembrane protein that mediates the active transport by the inward translocation of sodium down its electro-of iodide in the thyroid gland. Following cloning of NIS, NIS
chemical gradient to the driving of the simultaneous in-expression has been detected in a broad range of nonthyroidal
ward translocation of iodide against its electrochemicaltissues, suggesting that iodide transport in these tissues is con-
ferred by the expression of functional NIS protein. gradient. The sodium gradient as the driving force for
Methods. The aim of this study was to examine functional the iodide uptake is generated by Na1,K1-ATPase [1].
hNIS expression in kidney by reverse transcription-polymerase In addition to normally functioning thyroid tissue, a vari-chain reaction (RT-PCR), ribonuclease protection assay (RPA),
ety of extrathyroidal tissues, including salivary glands,immunohistochemistry, and Western blot analysis accompa-
gastric mucosa, and lactating mammary gland, have beennied by iodide accumulation studies in kidney cells.
Results. Using a pair of full-length hNIS-specific oligonucle- demonstrated to accumulate iodide [1]. Several studies
otide primers, RT-PCR followed by Southern hybridization suggest that iodide organification also occurs outside of
revealed hNIS mRNA expression in normal human kidney the thyroid gland [2, 3]. Since cloning and characteriza-tissue. The PCR products were subjected to automated se-
tion of hNIS [4–10], several studies have demonstratedquencing and revealed full identity with the published human
hNIS RNA and protein expression in a broad rangethyroid-derived NIS cDNA sequence. Furthermore, positive
protected bands indicating the presence of hNIS mRNA were of extrathyroidal tissues, including salivary and lacrimal
apparent in RPA gel lanes corresponding to human kidney glands, mammary gland, gastric and colonic mucosa, pan-
cells as well as Chinese hamster ovary (CHO) cells stably creas, ovary, prostate, testis, adrenal gland, heart, lung,transfected with hNIS cDNA and Graves’ thyroid tissue. Im-
and thymus, suggesting that iodide transport in thesemunohistochemical analysis of normal human kidney tissue
tissues is conferred by the expression of functional NISusing a mouse monoclonal hNIS-specific antibody showed
marked hNIS-specific immunoreactivity confined to tubular protein [11–14]. Iodide, which escaped trapping by the
cells, while no hNIS-specific immunoreactivity was detected in thyroid gland and other iodide-accumulating extrathy-
the glomeruli. NIS protein expression in human kidney cells roidal tissues, is excreted by the kidneys, which thereforewas further confirmed by Western blot analysis. In addition,
play an important role in the peripheral metabolism ofaccumulation of 125I was detected in human kidney cells in
iodine and thyroid hormones [15]. In addition to beingvitro and was shown to be sodium dependent and sensitive to
perchlorate. the most important route for the excretion of inorganic
Conclusions. Functional hNIS expression was demonstrated iodide, the kidney also stores more T3, T4, and inorganic
in the renal tubular system, suggesting that renal iodide trans- iodide per unit mass than other extrathyroidal tissuesport may be, at least in part, an active process driven by NIS.
[15]. Urinary excretion of inorganic iodide is thought to
occur through a combination of glomerular filtration and
partial tubular reabsorption as well as secretion ofThe human sodium iodide symporter (hNIS) repre-
plasma iodide, but the exact transport mechanisms ofsents an intrinsic membrane protein containing 13 trans-
iodide in the renal tubular system have remained un-membrane domains that mediate the active transport
known [15]. As hNIS is known to mediate the iodide
transport in the thyroid gland and probably in several
extrathyroidal tissues with known iodide accumulatingKey words: renal iodide transport, tubules, membrane protein, thyroid
tissue, clearance of iodide, transmembrane protein. activities, it may be hypothesized that iodide transport
in renal tubular cells is also driven by hNIS. Therefore,Received for publication January 20, 2000
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ern hybridization and sequence analysis, and by ribo- probe (nucleotides 1460 to 1477). Membranes were
nuclease protection assay (RPA). The recent availability washed with buffer 1 (0.1 mol/L maleic acid; 0.15 mol/L
of a high-affinity hNIS-specific antibody [16] offers the NaCl, pH 7.5) containing 0.3% (vol/vol) Tween-20 and
possibility of examining the expression of hNIS protein were then incubated in buffer 2 (1% blocking solution;
in kidney using immunohistochemistry and Western blot Boehringer Mannheim) in buffer 1 for 30 minutes. Fol-
analysis accompanied by measurement of iodide accu- lowing incubation in anti–DIG-alkaline phosphatase con-
mulation in kidney cells. jugate (dilution 1:10,000 in buffer 2) for 30 minutes, mem-
branes were washed twice in buffer 1 containing 0.3%
Tween-20 and then equilibrated in buffer 3 (0.1 mol/LMETHODS
Tris-HCl, 0.1 mol/L NaCl, 50 mmol/L MgCl2). Mem-RNA preparation, PCR amplification, and
branes were then incubated in disodium 3-(4 methyoxy-sequence analysis
spiro {1,2 dioxetane-3, 29-(59-chloro) triclo [3.3.1.13, 7]
Total RNA was isolated from normal human kidney decan}-4yl) phenyl phosphate (CSPD) (dilution 1:100 in
and Graves’ thyroid tissue obtained by surgery with ap- buffer 3) for five minutes and exposed to x-ray film for
proval by the Institutional Review Board by the modi- ten minutes.
fied acid guanidinium thiocyanate-phenol-chloroform
method according to Chomczynski and Sacchi [17] using Ribonuclease protection assay
the RNeasy Midi Kit (Qiagen, Valencia, CA, USA).
Total RNA was prepared from Chinese hamster ovarySingle-stranded oligo (dT)-primed cDNA was generated
(CHO) cells stably transfected with the pcDNA3 plasmidusing Superscript II Reverse Transcriptase (Life Tech-
containing hNIS cDNA (ERB4), their hNIS negativenologies, Gaithersburg, MD, USA). Oligonucleotide prim-
counterpart (ERB25), Graves’ thyroid tissue, and humaners used for analysis of hNIS RNA expression were GAG
kidney cells (G401, human Wilms’ tumor cell line; kindlyGTG GCA GGA CAG ACA GAC (nucleotides 81 to
provided by Dr. R. Kumar, Mayo Clinic, Rochester, MN,101: sense strand) and GGG CTT CTT GTT TCC AGT
USA), as described previously in this article. The anti-GGG (nucleotides 2130 to 2150: antisense strand). These
sense RNA probe for hNIS ribonuclease protectionprimers should generate a product that is 2070 bp in
assay (RPA) was transcribed from a 483 bp PCR productlength. Amplification was performed with 2 mL of each
with a T7 phage promoter at its 3-prime end, in thecDNA template, 50 pmol of each primer in 5 mL 10 3
presence of T7 RNA polymerase (10 U) and [a-32P]UTPreaction buffer (Boehringer Mannheim, Indianapolis,
IN, USA), and 2.6 units of Expand High Fidelity PCR (50 mCi) for labeling. The DNA template used for the
polymerase (Boehringer Mannheim) in a final volume PCR was a pcDNA3 plasmid containing full-length hNIS
of 50 mL. The amplification reaction was for 40 cycles, cDNA (kindly provided by Dr. S.M. Jhiang, Ohio State
and each cycle consisted of 948C for 1 minute (denatur- University, Columbus, OH, USA). The resulting high
ation), 658C for 2 minutes (annealing), and 728C for 3 specific-activity probe encompasses nucleotides 1184 to
minutes (extension) followed by a final 10-minute elon- 1667 of the hNIS cDNA sequence. The antisense RNA
gation at 728C. probe for human glyceraldehyde 3-phosphate dehydro-
To control the integrity of the cDNA templates and genase (GAPDH) RPA was generated from pTRI-
to rule out DNA contamination carried over in the sam- GAPDH human antisense control template (Ambion,
ples, all templates were amplified with intron-spanning Austin, TX, USA). This probe was designed to detect a
primers that were designed to amplify a portion of the 154 bp fragment of human GAPDH mRNA. Total RNA
human b-actin gene (nucleotides 1288 to 1905). The ex- (10 mg of CHO cell RNA and Graves’ thyroid tissue
pected b-actin product from a cDNA template is 440 bp.
RNA, 80 mg of human kidney cell RNA) was combined
Reaction conditions were as stated previously in this
with hNIS and GAPDH probes (500,000 cpm) in hybrid-article.
ization buffer, denatured at 958C, and hybridized at 458CFollowing polymerase chain reaction (PCR) amplifi-
for 16 hours. RNase A (0.175 U) and RNase T1 (25 U;cation, PCR products were gel-purified using the Aga-
RNase Protection Kit; Boehringer Mannheim) wererose Gel DNA Extraction Kit (Boehringer Mannheim)
added to the solution and incubated for one hour at 378Cand were subjected to automated sequencing.
to digest nonhybridized RNA and probe. Samples were
Southern blot analysis subsequently digested with proteinase K (50 mg) in the
presence of 0.5% sodium dodecyl sulfate (SDS) and wereTen microliters of each PCR product were separated
extracted with phenol/chloroform/isoamyl alcohol. Theon 1% agarose gels, stained with ethidium bromide, and
resulting ethanol-precipitated protected fragments weretransferred to positively charged nylon membranes (Qia-
resuspended in loading buffer and resolved on a denatur-gen). Hybridization was carried out with a digoxigenin
(DIG)-labeled internal hNIS-specific oligonucleotide ing polyacrylamide gel (5% acrylamide/8 mol/L urea).
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Immunohistochemical staining antibodies replaced in turn by PBS and isotype-matched
nonimmune IgGs (Sigma) were routinely examined toParaffin-embedded tissue sections derived from nor-
ensure specificity and to exclude cross-reactivities be-mal human kidney tissue (N 5 6) were first deparaffin-
tween the antibodies and conjugates employed.ized by serial passages in xylene and were then subjected
to a graded series of alcohol washes, and finally endoge-
Membrane preparationnous peroxidase activity was blocked by incubation in a
50% by volume solution of 3% H2O2/methanol for 10 Membrane proteins were prepared from human
minutes. Subsequently, slides were pretreated by heating Graves’ thyroid tissue and human kidney cells (G401)
in citrate buffer (10 mmol/L citric acid) for 30 minutes. by a modification of a previously described procedure
Following blocking of nonspecific binding sites by apply- [21]. In brief, kidney cells plated on 100 mm dishes were
ing 5% normal goat serum (NGS) diluted in phosphate- washed with PBS, harvested, and resuspended in buffer
buffered saline (PBS)/0.05% Tween-20 (PBS-T) for 30 A [250 mmol/L sucrose, 10 mmol/L HEPES, pH 7.5,
minutes, slides were incubated with antibodies directed 1 mmol/L ethylenediaminetetraacetic acid (EDTA), 10
against human NIS, human lysozyme, human epithelial
mg/mL leupeptin, 10 mg/mL aprotinin, and 1 mmol/L phe-
membrane antigen (EMA) and human Tamm-Horsfall nylmethylsulfonyl fluoride (PMSF)]. The homogenate
glycoprotein, respectively, at four predetermined opti-
was centrifuged twice at 500 3 g for 15 minutes at 48C.
mal concentrations in 1% NGS-PBS-T for one hour at
Following centrifugations, 100 mL 1 mol/L Na2CO3/mLroom temperature:
buffer A was added to the supernatant and incubated(1) Mouse monoclonal hNIS-specific antibody (di-
at 48C for 45 minutes with continuous shaking. Then arected against amino acid residues 468 to 643 of hNIS)
further centrifugation at 100,000 3 g was performedwas applied at a dilution of 1:1600. This antibody has
for 15 minutes, and the pellet was resuspended in anbeen extensively characterized and demonstrated to spe-
appropriate volume of buffer B consisting of 250 mmol/Lcifically recognize hNIS by Western blotting and immu-
sucrose, 10 mmol/L HEPES, pH 7.5, and 1 mmol/L MgCl2.nohistochemical staining [16].
Graves’ thyroid tissue obtained by surgery was homoge-(2) Rabbit polyclonal antibody to lysozyme, which
nized in buffer C (250 mmol/L sucrose, 10 mmol/L Tris-stains positive for lysozyme present in renal proximal
HCl, pH 7.5, 1 mmol/L MgCl2, 40 mg/L aprotinin, 1 mmol/Ltubular cells (BioGenex, San Ramon, CA, USA), was
PMSF, 4 mg/L leupeptin). The homogenate was centri-applied at a dilution of 1:100 [18].
fuged at 1500 3 g for five minutes at 48C. Following(3) Mouse monoclonal antibody to EMA, which stains
centrifugation, 100 mL 1 mol/L Na2CO3/mL buffer C waspositive for EMA present in renal distal tubular cells and
added to the supernatant and incubated at 48C for 45collecting ducts (BioGenex), was applied at a dilution of
1:100 [19]. minutes with continuous shaking. Then a further centrif-
(4) Rabbit polyclonal antibody to human Tamm-Hors- ugation at 100,000 3 g was performed for 15 minutes,
fall glycoprotein, which stains positive for Tamm-Hors- and the pellet was resuspended in an appropriate volume
fall glycoprotein in the thick ascending loop of Henle of buffer C. Protein concentrations were determined by
(Biomedical Technologies Inc., Stoughton, MA, USA), a protein assay (Bio-Rad DC Protein Assay; Bio-Rad,
was applied at a dilution of 1:200 [20]. Hercules, CA, USA).
Tissue sections were washed with PBS-T and incu-
bated with biotin-SP-conjugated goat-anti-mouse IgG Western blot analysis
and goat-anti-rabbit IgG, respectively (diluted 1:200 in For Western blot analysis, the NuPAGE electrophore-
1% NGS-PBS-T) for 20 minutes prior to a 20-minute
sis system (NOVEX, San Diego, CA, USA) was used.
incubation with peroxidase-conjugated streptavidin (di-
Aliquots of membrane protein (15 mg) prepared fromluted 1:300 in 1% NGS-PBS-T; Dako, Glostrup, Den-
human Graves’ thyroid tissue and human kidney cellsmark). Slides were then treated with sodium acetate
were solubilized for 30 minutes at 378C in the samesolution (pH 5.2) for two minutes followed by incubation
volume of reducing sample buffer (0.125 mol/L Tris-with 3-amino-9-ethyl-carbazole (AEC) substrate solu-
HCl, pH 6.8, 4% SDS, 10% b-mercaptoethanol, 20%tion (Sigma, St. Louis, MO, USA) for 15 minutes, yield-
glycerol) and loaded onto 4 to 12% Bis-Tris-HCl–ing a red precipitate indicative of NIS-specific immu-
buffered polyacrylamide gels. Following gel electropho-noreactivity. Tissue sections were counterstained with
resis for one hour, proteins were transferred to nitrocel-hematoxylin for five minutes prior to mounting.
lulose membranes using electroblotting. Membranes wereThe NIS immunostaining was repeated following pre-
then preincubated for one hour in 5% low-fat dried milkincubation of the mouse monoclonal hNIS-specific anti-
in TBS-T (20 mmol/L Tris, 137 mmol/L NaCl, and 0.1%body with an excess of the corresponding peptide. Paral-
lel tissue sections with the primary and secondary Tween-20) to block nonspecific binding sites. Mem-
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branes were then incubated with a mouse monoclonal
antibody directed against amino acid residues 468 to 643
of human NIS (dilution 1:3000) [16] for two hours at
room temperature. After washing with TBS-T, horserad-
ish peroxidase-labeled goat-anti-mouse antibody was ap-
plied (dilution 1:5000) for one hour at room temperature
prior to incubation with ECL Western blotting detection
reagents (Amersham, Arlington Heights, IL, USA) for
one minute. Exposures were made at room temperature
for approximately one minute using Kodak BIOMAX
MR films. Prestained protein molecular weight standards
(Life Technologies) were run in the same gels for com-
parison of molecular weight and estimation of transfer
efficiency. The same procedure was repeated following
preincubation of the mouse monoclonal hNIS-specific
antibody with an excess of the corresponding peptide.
For deglycosylation of the membrane proteins, 20 mg
of membrane fractions were denatured in the denaturing
buffer (0.5% SDS, 1% b-mercaptoethanol) for 30 min-
utes at 378C. Denatured proteins were treated with 1 mL
(500 U) of N-glycosidase-F (New England Biolabs, Bev-
erly, MA, USA) in 50 mmol/L sodium phosphate buffer
(pH 7.5) containing 1% NP-40 at 378C overnight. The
deglycosylation reaction was quenched by adding the
same volume of reducing sample buffer (0.125 mol/L
Tris-HCl, pH 6.8, 4% SDS, 10% b-mercaptoethanol,
20% glycerol).
Iodide uptake studies
Uptake of 125I by human kidney cells (G401) was deter-
mined at steady-state conditions as described by Weiss,
Philp, and Grollmann [22]. In brief, cells were plated on
six-well plates (2 3 105 cells/well), and iodide uptake
studies were performed in Hank’s balanced salt solution
(HBSS) supplemented with 10 mmol/L NaI, 0.1 mCi Na
125I/mL, and 10 mmol/L HEPES at pH 7.3; 10 mmol/L
KClO4 were added to control wells. Trapped iodide was
removed from cells by a 20-minute incubation in 1 N
NaOH and measured by g-counting.
Sodium dependency of iodide accumulation
By substituting choline chloride for sodium chloride
in the HBSS used for iodide uptake measurement, the
effect of the sodium concentration (20 to 140 mmol/L)
on iodide accumulation in human kidney cells was exam-
ined.
Fig. 1. Polymerase chain reaction (PCR) amplification of cDNA derivedRESULTS
from human Graves’ thyroid tissue (lane 1) and normal human kidney
tissue (lane 2) using a pair of hNIS-specific oligonucleotide primers de-PCR amplification, Southern blot analysis, and
signed to amplify full-length hNIS cDNA (2070 bp; A). All samples weresequence analysis
coamplified with a pair of b-actin oligonucleotide primers designed to
amplify a 440 bp fragment of the b-actin gene (B). Human NIS-specificTotal RNA was prepared from normal human kidney
transcripts were confirmed by Southern hybridization using a DIG-la-and Graves’ thyroid tissue followed by RT-PCR with a
beled internal hNIS-specific oligonucleotide probe (C). Lane M, 1 kb
pair of hNIS-specific oligonucleotide primers designed PLUS ladder (A), 100 bp ladder (B); lane 1, human Graves’ thyroid
tissue; lane 2, human kidney tissue; lane 3, negative control (no cDNA).to amplify full-length hNIS DNA (Fig. 1A). To monitor
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counterpart (ERB25), human Graves’ thyroid tissue and
human kidney cells (G401), and analyzed by RPA. Posi-
tive protected bands at 483 bp indicating the presence
of hNIS mRNA were apparent in RPA gel lanes corre-
sponding to ERB4, Graves’ thyroid tissue, and human
kidney cells. No NIS mRNA was detected in ERB25.
RPA of GAPDH mRNA was performed to monitor
RNA integrity and quantity showing positive protected
bands at 154 bp for human Graves’ thyroid tissue and
kidney cells and at approximately 90 bp for CHO cells
(corresponding to human and hamster GAPDH, respec-
tively; Fig. 2).
Immunohistochemical staining
Immunostaining of paraffin-embedded tissue sections
derived from normal human kidney tissue using a mouse
monoclonal hNIS antibody revealed marked hNIS-
specific immunoreactivity confined to tubular cells with
more prominent staining in the distal tubular system
(Fig. 3 A–D), while no NIS-specific immunoreactivity
was detected in the glomeruli (Fig. 3A, arrow). NIS-
specific immunoreactivity in the proximal tubular system
seemed to be more prominent at the basolateral aspect
of tubular cells (Fig. 3C), while NIS-specific immunore-
activity in the distal tubular system was more diffuse
throughout the cytoplasm of distal tubular cells (Fig.
3D). NIS-specific staining in the distal tubular system
was present in all nephron segments, including medullary
Fig. 2. Ribonuclease protection assay (RPA) of human sodium iodide and cortical distal tubules as well as collecting ducts.
symporter (hNIS) and GAPDH mRNA derived from Chinese hamster Parallel control sections stained with primary and sec-
ovary (CHO) cells stably transfected with hNIS cDNA (ERB4), their
ondary antibodies replaced in turn by PBS and isotype-hNIS cDNA negative counterpart (ERB25), human Graves’ thyroid
tissue, and human kidney cells. Lane 1, molecular standards; lane 2, matched nonimmune mouse immunoglobulins were con-
undigested probe; lane 3, digested probe; lane 4, ERB25; lane 5, ERB4; sistently negative (Fig. 3 E, F). Following preabsorption
lane 6, Graves’ thyroid tissue; lane 7, human kidney cells. Positive
of the mouse monoclonal hNIS-specific antibody withprotected bands at 483 bp (corresponding to hNIS mRNA) are apparent
in lanes containing RNA derived from ERB4, Graves’ thyroid tissue, an excess of corresponding peptide, no NIS-specific im-
and kidney cells. No NIS mRNA was detected in ERB25. Positive munoreactivity was detected (Fig. 3 G, H).
protected bands at 154 bp (human thyroid tissue and kidney cells) and
To determine the nephron segment origin of tubularapproximately 90 bp (CHO cells; corresponding to human and hamster
GAPDH, respectively) are apparent in lanes 4 through 7. cells that stained positive for NIS protein more precisely,
serial sections of normal human kidney were stained
using antibodies to NIS protein (Fig. 4A), to lysoszyme
present in proximal tubules (Fig. 4B, long arrows), to
cDNA integrity and quantity, samples were coamplified EMA present in distal tubules and collecting ducts (Fig.
with a pair of human b-actin primers (Fig. 1B). Human 4C, short arrows), and to human Tamm-Horsfall glyco-
NIS-specific transcripts were confirmed by Southern hy- protein present in the thick ascending loop of Henle
bridization using a DIG-labeled internal hNIS-specific (Fig. 4D, open arrows), respectively. A comparison of
oligonucleotide probe (Fig. 1C). RT-PCR and Southern the same regions on serial sections of kidney tissue al-
hybridization revealed full-length hNIS mRNA expres- lowed localization of NIS-specific immunoreactivity to
sion in Graves’ thyroid tissue and normal human kidney proximal tubulus, distal tubules, and collecting ducts as
tissue. Sequencing of the PCR products revealed full well as the thick ascending loop of Henle.
identity with the published human thyroid-derived NIS
Western blot analysiscDNA sequence [5].
Using a mouse monoclonal hNIS-specific antibody,
RPA Western blot analysis of membrane protein prepared
Total RNA was prepared from CHO cells stably trans- from human kidney cells revealed a band of a molecular
weight of approximately 80 kD, while membrane proteinfected with hNIS cDNA (ERB4) and their hNIS negative
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Fig. 4. Serial sections of normal human kidney were stained using antibodies to NIS protein (A), to lysoszyme present in proximal tubules (B,
long arrows), to EMA present in distal tubules and collecting ducts (C, short arrows), and to human Tamm-Horsfall glycoprotein present in the
thick ascending loop of Henle (D, open arrows), respectively. A comparison of the same regions on serial sections of kidney tissue allowed to
localize NIS-specific immunoreactivity to proximal tubulus, distal tubules, and collecting ducts as well as the thick ascending loop of Henle (original
magnification 3200).
prepared from Graves’ thyroid tissue revealed a major human kidney cells was approximately 55 kD, which
represents the molecular weight of hNIS in human thy-band of a molecular weight of approximately 100 kD
(Fig. 5A). This band was not detected following preab- roid tissue [23].
sorption of the antibody with an excess of the corre-
Iodide uptake studiessponding peptide (Fig. 5B). The differences in the molec-
ular weights of detected bands specific for NIS protein Iodide uptake in human kidney cells reached half-
maximal levels within 5 to 10 minutes and became satu-in thyroid tissue and kidney cells have been shown to
be due to different degrees of NIS protein glycosylation. rated at 40 to 50 minutes (Fig. 6A). In contrast to control
cell lines, including CHO cells, COS-7 cells, human leu-The molecular mass of deglycosylated hNIS protein in
b
Fig. 3. Immunostaining of paraffin-embedded tissue sections derived from normal human kidney using mouse monoclonal hNIS antibody revealed
marked hNIS immunoreactivity (red precipitate) confined to tubular cells (A and B, original magnification 3400; C and D, original magnification
31000) with more prominent staining in the distal tubular system (B and D), while no NIS-specific immunoreactivity was detected in the glomeruli
(A, arrow). NIS-specific immunoreactivity in the proximal tubular system seemed to be more prominent at the basolateral aspect of tubular cells
(C), while NIS-specific immunoreactivity in the distal tubular system was more diffuse throughout the cytoplasm of distal tubular cells (D). NIS-
specific staining in the distal tubular system was present in all nephron segments, including medullary and cortical distal tubules as well as collecting
ducts. Parallel control sections using isotype-matched nonimmune immunoglobulin (E and F, original magnification 31000) were negative. Following
preabsorption of the mouse monoclonal hNIS-specific antibody, no NIS-specific immunoreactivity was detected (G and H, original magnification
31000).
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Fig. 5. Western blot analysis of membrane proteins derived from human Graves’ thyroid tissue (A, lane 1) and human kidney cells (A, lane 2;
B) using a mouse monoclonal hNIS-specific antibody. hNIS protein was detected as a band of approximately 80 kD in human kidney cells, which
was not detected following preabsorption of the antibody with corresponding peptide (B, lane 2). In human Graves’s thyroid tissue, hNIS protein
was detected as a major band of approximately 100 kD.
kemia, and prostate cancer cells, which did not show io- tissues [4–10, 16]. We and others have demonstrated
dide accumulation, human kidney cells accumulated 125I hNIS RNA and protein expression in a variety of nonthy-
approximately eightfold more than human kidney cells roidal tissues, including salivary and lacrimal glands, gas-
coincubated with 10 mmol/L perchlorate, a known com- tric and colonic mucosa, and pancreas. These data sug-
petitive inhibitor of thyroidal iodide uptake (Fig. 6B) [1]. gest that NIS is responsible for extrathyroidal iodide
transport that is known to be mediated by an active
Sodium dependency of iodide accumulation
translocating system and maintains an iodide gradient
When substituting choline chloride for sodium chlo- between secreted fluid and serum [11–14]. In the present
ride, human kidney cells revealed an almost linear in- study, we demonstrate full-length hNIS RNA and pro-
crease of iodide uptake with increasing extracellular so- tein expression in human kidney cells that also reveal
dium concentration (20 to 140 mmol/L; Fig. 7). perchlorate sensitive and sodium-dependent iodide accu-
mulation in vitro.
In contrast to our current data, in a former study, weDISCUSSION
were not able to detect NIS mRNA expression in humanThe hNIS is a transmembrane protein that catalyzes
kidney using Northern blot analysis [11]. Similarly,iodide uptake in thyroid follicular cells, thereby provid-
Smanik et al reported no NIS RNA expression in kidneying iodide as a substrate for thyroid hormone synthesis
using RT-PCR [7]. These contrasting data are most likely[1]. Extensive characterization of hNIS since its cloning
due to variable levels of hNIS gene expression in differ-in 1996 and generation of high-affinity hNIS antibodies
ent kidney segments, as we found most prominent hNIS-have facilitated analysis of hNIS expression, distribution,
and cellular localization in thyroidal and extrathyroidal specific immunoreactivity in the distal tubular system,
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Fig. 7. Sodium dependency of iodide uptake by human kidney cells.
Results represent means 6 SEM of triplicate experiments and are
expressed as the amount of iodide accumulation in counts per minute
(cpm).
dine uptake in a renal cyst on diagnostic 131I imaging
[26], very recently, 131I accumulation has been reported
in a large renal cyst on post-therapeutic whole body
imaging scan, supporting the concept that iodide is sub-
ject to an active secretory process by the renal tubule
[27]. In addition, transient enhancement and increased
attenuation of renal cysts have been observed on delayed
computed tomography scanning after the administration
of iodinated contrast media [28]. Possible mechanisms
for iodide entering renal cysts include communicationFig. 6. Time course of iodide uptake in human kidney cells (A), which
accumulate 125I about eightfold more (B; lane 1) than kidney cells with the collecting system, diffusion from renal sinus
coincubated with 10 mmol/L perchlorate (B; lane 2). Control cell lines, lymphatics, and active iodide secretion as cyst epithelia
including CHO cells (B, lane 3), COS-7 cells (B, lane 4), human leuke-
are known to resemble tubular epithelium and exhibitmia (B, lane 5), and prostate cancer cells (B, lane 6) did not show
iodide accumulation. Results represent means 6 SEM of triplicate secretory activity [29]. In the previously mentioned pa-
experiments and are expressed as the amount of iodide accumulation tient, the avascular, nonfunctional nature of the renalin counts per minute (cpm).
cyst suggested active secretion of the iodide. It has been
postulated that iodide enters the basolateral aspect of
the cell through the Na/K/2 Cl cotransporter and exits the
with lower staining in the proximal tubules and no hNIS- cell via the apical CFTR (cystic fibrosis transmembrane
specific immunostaining in the glomeruli. regulator) chloride channel, thereby mediating the active
Several studies suggest that organification of iodide, transcellular secretion of iodide into the cyst lumen [27].
which is essential for a possible functional activity of With the detection of functional full-length hNIS RNA
trapped iodide in nonthyroidal tissues, is not restricted and protein expression in human kidney in our current
to thyroid tissue [2, 3]. Possible functions of trapped and study, it is likely that hNIS is responsible for the secretion
organified iodide in extrathyroidal tissues may include of 131I into renal cysts and therefore iodide transport in
antiproliferative and antioxidative effects, as demon- the renal tubular system. Western blot analysis showing
strated for certain iodolipids (iodiolactones, iodoalde- NIS protein expression in membrane preparations of
hydes) in the thyroid gland [24]. Interestingly, a-iodo- human kidney cells, detection of NIS-specific iodide ac-
cumulating activity in human kidney cells in vitro as wellhexadecanal, a naturally occurring iodoaldehyde, has
been shown to inhibit adenylyl cyclase in kidney cortex as immunohistochemical data, that show generalized,
predominantly cytoplasmic NIS-specific immunoreactiv-in a similar fashion to its activity in thyroid cells [25].
Further investigations are needed to address iodide or- ity throughout the proximal and distal tubular system,
including collecting ducts and the thick ascending loopganification in the kidney and its physiological role.
Following a former report of “false positive” radioio- of Henle suggest that NIS may mediate transepithelial
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Department of Nephrology, Mayo Clinic, Rochester, MN, for providingas well as intracellular iodide transport in kidney. Further
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function of NIS in the renal tubular system more pre- Rochester, MN for their advice.
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